


## TRPV3 antagonist 74a

<b>Cat. No.:</b>	HY-131868		
<b>CAS No.:</b>	1432051-63-2		
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>17</sub> F <sub>3</sub> N <sub>2</sub> O <sub>2</sub>		
<b>Molecular Weight:</b>	338.32		
<b>Target:</b>	TRP Channel		
<b>Pathway:</b>	Membrane Transporter/Ion Channel; Neuronal Signaling		
<b>Storage:</b>	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



### BIOLOGICAL ACTIVITY

<b>Description</b>	TRPV3 antagonist 74a is a potent and selective TRPV3 antagonist. TRPV3 antagonist 74a displays no significant activity against a panel of other ion channels. TRPV3 antagonist 74a can be used for the research of neuropathic pain <sup>[1][2]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	TRPV3								
<b>In Vitro</b>	TRPV3 antagonist 74a (100 μM; 2300 seconds; keratinocytes) largely attenuates SLIGRL or SLIGKV-induced Ca <sup>2+</sup> responses <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
<b>In Vivo</b>	<p>TRPV3 antagonist 74a (150 μg; intradermal injection; 30 minutes) decreases the number of scratches significantly<sup>[2]</sup>. .TRPV3 antagonist 74a (10~100 mg/kg; p.o.) dose-dependently attenuates mechanical allodynia induced by von Frey hair stimulation to the ipsilateral (injured) hind paw. TRPV3 antagonist 74a exhibits anti-nociceptive activity in the reserpine model of central pain by increasing muscle pressure threshold<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>WT mice</td> </tr> <tr> <td>Dosage:</td> <td>150 μg</td> </tr> <tr> <td>Administration:</td> <td>Intradermal injection; 30 minutes</td> </tr> <tr> <td>Result:</td> <td>The number of scratches decreased significantly.</td> </tr> </table>	Animal Model:	WT mice	Dosage:	150 μg	Administration:	Intradermal injection; 30 minutes	Result:	The number of scratches decreased significantly.
Animal Model:	WT mice								
Dosage:	150 μg								
Administration:	Intradermal injection; 30 minutes								
Result:	The number of scratches decreased significantly.								

### REFERENCES

[1]. Gomtsyan A, et al. Synthesis and Pharmacology of (Pyridin-2-yl)methanol Derivatives as Novel and Selective Transient Receptor Potential Vanilloid 3 Antagonists. *J Med Chem.* 2016;59(10):4926-4947.

[2]. Zhao J, et al. PAR2 Mediates Itch via TRPV3 Signaling in Keratinocytes. *J Invest Dermatol.* 2020;140(8):1524-1532.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA